Starling Oncology, Inc. cotiza a 6.70 USD y tiene una capitalización bursátil de $683M. En los últimos 12 meses ha facturado $587M con un margen de flujo de caja libre del -5.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.08 | $-0.02 | $-0.06 |
| Estimado | $-0.05 | $-0.06 | $-0.09 | $-0.09 |
| Sorpresa | — | -33.3% | +77.8% | +33.3% |
| Métrica | STLN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -7.2% | -38.6% | +31.4% |
| Net Margin | -12.1% | -33.6% | +21.5% |
| FCF Margin | -5.5% | -13.9% | +8.3% |
| ROE | — | -40.4% | — |
| ROA | -36.8% | -32.0% | -4.8% |
| Current Ratio | 1.59 | 2.84 | -1.25 |
| Debt / Equity | -4.92 | 0.28 | -5.20 |